| Literature DB >> 29474441 |
Mikael B Jensen-Johansen1, Mia S O'Toole2, Søren Christensen2, Heiddis Valdimarsdottir3,4, Sandra Zakowski5, Dana H Bovbjerg6,7, Anders B Jensen8, Robert Zachariae2.
Abstract
The objective was to examine the effect of Expressive Writing Intervention (EWI) on self-reported physical symptoms and healthcare utilization in a nationwide randomized controlled trial with Danish women treated for primary breast cancer, and to explore participant characteristics related to emotion regulation as possible moderators of the effect. Women who had recently completed treatment for primary breast cancer (n = 507) were randomly assigned to three 20 min. home-based writing exercises, one week apart, focusing on emotional disclosure (EWI) of a distressing experience (their cancer or a non-cancer topic) or a non-disclosing topic (control). Outcomes were self-reported physical symptoms and healthcare utilization (visits and telephone contacts with GP) 3 and 9 months post-intervention. Potential moderators were repressive coping, alexithymia, rumination, social constraints, and writing topic. Results revealed no group by time interaction effects for any outcomes. Moderation analyses showed that 1) low alexithymic women in the EWI group showed larger decreases in GP telephone calls over time than both high alexithymic women and controls and 2) women in the EWI group writing about their own cancer, but not women writing about other topics, showed a larger decrease than controls. The results from this large randomized trial are concordant with previous findings showing that EWI is unlikely to be a generally applicable intervention to improve health-related outcomes in cancer patients and cancer survivors. However, written disclosure might have a beneficial impact for individuals who write about their own cancer, as well as for those low in alexithymia.Entities:
Mesh:
Year: 2018 PMID: 29474441 PMCID: PMC5825018 DOI: 10.1371/journal.pone.0192729
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1CONSORT study flow diagram.
Descriptive statistics and baseline differences.
| Variables | EWI group | CTRL group | |||
|---|---|---|---|---|---|
| N | M (SD) | N | M (SD) | ||
| Sample size (N) | 253 | - | 254 | - | - |
| Age | 253 | 53.6 (9.0) | 254 | 53.6 (9.2) | 0.994 |
| Married/cohabiting (%) | 202 | 80% | 205 | 81% | 0.806 |
| DBCG treatment protocols | |||||
| A (%) | 62 | 25% | 58 | 23% | 0.658 |
| B (%) | 68 | 27% | 79 | 31% | 0.295 |
| C (%) | 68 | 27% | 73 | 29% | 0.640 |
| D (%) | 55 | 22% | 44 | 17% | 0.210 |
| Nodal status (≥1) (%) | 104 | 41% | 113 | 45% | 0.442 |
| Mastectomy (%) | 96 | 38% | 99 | 39% | 0.811 |
| Tumorectory (%) | 157 | 64% | 155 | 61% | 0.811 |
| Radiotherapy (%) | 195 | 77% | 197 | 78% | 0.897 |
| PHQ T1 | 249 | 6.81 (4.02) | 252 | 6.40 (4.03) | 0.108 |
| PHQ T2 | 201 | 7.00 (3.88) | 226 | 6.62 (4.05) | - |
| PHQ T3 | 208 | 7.08 (4.11) | 223 | 6.72 (4.33) | - |
| GP visit T1 | 202 | 2.08 (3.2) | 223 | 2.03 (2.5) | 0.849 |
| GP visit T2 | 186 | 1.61 (1.21) | 205 | 1.66 (1.83) | - |
| GP visit T3 | 188 | 1.21 (1.61) | 204 | 1.32 (1.35) | - |
| GP-phone T1 | 204 | 1.12 (1.71) | 217 | 1.23 (1.98) | 0.551 |
| GP-phone T2 | 186 | 0.89 (1.61) | 206 | 0.86 (1.37) | - |
| GP-phone T3 | 187 | 0.80 (1.27) | 203 | 0.95 (1.31) | - |
*) Treatment protocols: A: -CEF, _Tam, _RT [ER+ and Ts<20 mm and (Grade I or non-ductal) & N0 & age ≥35 year]; B: +CEF, +Tam [(ER+ or ER unknown) and pre-menopausal]; C: _CEF, +Tam (ER+ and post-menopausal); D: +CEF, _Tam [ER_ and (pre-menopausal or post-menopausal)]. Abbreviations: ER/PR+/_, estrogen/progesterone receptor status positive/negative; N0/≥1, lymph node status negative/positive; Ts. tumor size; RT, radiotherapy; CEF, cyclophosphamide, epirubicin, and fluorouracil; TAM, tamoxifen.
Results from MLMs (baseline, 3- and 9 month follow-up) (Time × Group) of physical symptoms (PHQ), number of GP visits, and number of GP telephone contacts (2a), and results of moderation analyses with repressive coping (2b), social constraints (SCS-C) (2bc), rumination (ECQ) (2d), alexithymia (TAS-20) (2e), and writing topic (own cancer vs. other topic vs. neutral writing) included as moderators.
| EWI vs. CTRL | |||
|---|---|---|---|
| Effect | |||
| B (SE) | |||
| Time | 0.03 (< .01) | .291 | 0.09 |
| Time x Group | <0.01 (.01) | .854 | 0.02 |
| Time | |||
| Time x Group | 0.01 (.01) | .363 | 0.09 |
| Time | |||
| Time x Group | 0.01 (.02) | .543 | 0.06 |
| PHQ | -0.02 (.01) | .055 | 0.17 |
| GP-visit | 0.06 (.03) | .090 | 0.16 |
| GP-phone | -0.01 (.05) | .806 | 0.03 |
| PHQ | <-0.01 (< .01) | .869 | 0.01 |
| GP visit | <0.01 (< .01) | .257 | 0.10 |
| GP-phone | <0.01 (< .01) | .676 | 0.04 |
| PHQ | <0.01 (< .01) | .927 | 0.03 |
| GP-visit | <0.01 (< .01) | .575 | 0.05 |
| GP-phone | <-0.01 (< .01) | .537 | 0.06 |
| PHQ | <-0.01 (< .01) | .515 | 0.06 |
| GP-visit | <0.01 (< .01) | .657 | 0.04 |
| GP-phone | <-0.01 (< .01) | ||
| PHQ | 2.84 | .242 | 0.15 |
| GP-visit | |||
| GP-phone | |||
Notes: MLM: Multilevel Linear Models; d: Cohen’s d; a = Continued to be statistically significant (p<0.05) when including age and depressive symptoms (BDI-SF) in the model as covariates; b = Statistically significant (p<0.05) only when included, without covariates the result was trend-wise significant (p = 0.052), B(SE) = unstandardized parameter in the MLMs and its standard error; χ2 = chi square test for between-group differences over time.
Fig 2Alexithymia as moderator: Mean number of telephone contacts with general practitioner (GP) (Error bars: 95%CI) from baseline to follow-up of high and low alexithymic women in the EWI and neutral writing control group.
Fig 3Writing topic as moderator: Mean number of visits to general practitioner (GP) (Error bars: 95%CI) from baseline to follow-up of EWI participants writing about their own cancer, EWI participants writing about other topics, and neutral writing controls.
Fig 4Writing topic as moderator: Mean number of telephone contacts with general practitioner (GP) (Error bars: 95%CI) from baseline to follow-up of EWI participants writing about their own cancer, EWI participants writing about other topics, and neutral writing controls.